DXCM · NASDAQ · STOCK
DexCom (DXCM) Stock Analysis
$91.06
52W $54.11 – $92.56
63/100
$34.85B
35.7
1.41
Is DXCM Bullish or Bearish?
Bullish.
Innellis AI committee rates Dexcom (DXCM) Buy with a composite score of 63/100
, based on 6 analysts with 50% agreement.
Last updated August 24, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +11.86 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -8.14 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- ROE of 36.2% shows genuine earnings power backing the valuation — Value
- EPS growing 79.4% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 34.5 is moderate-to-rich — Value
- Price-to-book of 9.4x prices in significant intangible value — Value
- RSI at 75 is in overbought territory — Technical
- Weekly RSI at 79 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 29.1% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 24, 2026
Overall Committee Score
63/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 20%
of 192 Healthcare peers
Value Analyst
neutral
54
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 36.2% shows genuine earnings power backing the valuation
− P/E of 34.5 is moderate-to-rich
Growth Analyst
bullish
79
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 79.4% YoY
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 75 is in overbought territory
Risk Analyst
neutral
52
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
− Bollinger bandwidth of 29.1% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
70
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.40 across 15 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3069.37)
Investment Thesis Evolution
Committee score moved marginally from 63.1 to 63.1.
Comparing 2026-08-23 to 2026-08-24 (1 day apart).
Technical Analysis
RSI (14)
74.5
Overbought
MACD Histogram
0.188
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$91.84
Resistance
$93.17
Bollinger %B
0.78
Inside Bands
Price vs Moving Averages
EMA 9
$89.48
Above
EMA 21
$85.60
Above
EMA 50
$79.66
Above
EMA 200
$72.93
Above
Fundamental Analysis
Valuation
39
Growth
95
Profitability
100
Financial Health
88
Cash Flow
70
Valuation
P/E Ratio
35.7×
P/B Ratio
13.52×
PEG Ratio
0.47
Dividend Yield
0.00%
52W High
$92.56
52W Low
$54.11
Quality & Growth
ROE
3045.5%
ROA
1319.1%
Gross Margin
6247.3%
Operating Margin
2292.3%
Revenue Growth YoY
—
Debt / Equity
0.53
AI Fundamental Assessment
P/E ratio of 35.7 (rich relative to a 15-40x range); Price-to-book of 13.5x; PEG ratio of 0.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 30.5%; Return on assets of 13.2%; Net margin of 20.1%; Gross margin of 62.5%; Current ratio of 1.73 (healthy short-term liquidity); Debt-to-equity of 0.53; Free cash flow per share is positive (3.66); Most recent quarter beat estimates by 12.4%; 5 consecutive earnings beats; EPS growth accelerating (+0.0% -> +25.0% QoQ); Average YoY EPS growth of 45.8%; Analyst estimates rising over recent quarters
Get the Full DXCM Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →